Alkindi® is the first preparation of hydrocortisone specifically designed for and studied in children suffering from pediatric adrenocortical insufficiency (AI). Alkindi® is a patented, oral, immediate-release formulation of hydrocortisone granules in capsules for opening which allows accurate age-appropriate dosing in particular infants and children. This therapeutic approach has the potential to help young patients less than eighteen years of age suffering from pediatric AI and the related condition congenital adrenal hyperplasia (CAH).
Alkindi® is already approved and marketed in the European Union as well as in the USA. EffRx has an exclusive license agreement with Diurnal Group plc, a listed UK-headquartered specialty pharmaceutical company, for the registration and commercialization of Alkindi® in Switzerland.
EffRx has obtained the Swiss Marketing Authorization for Alkindi® as replacement therapy for adrenal insufficiency in infants, children and adolescents (from birth to less than eighteen years) at the end of 2020.
Alkindi® is now available to patients within Switzerland, where there are approximately 200 individuals suffering from pediatric AI.
For more information about Alkindi® see www.swissmedicinfo.ch